| 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. | |
| | |
MedLine Citation:
|
PMID: 17268018 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PET using 18F-FDG has been shown to effectively detect various types of cancer by their increased glucose metabolism. The aim of this study was to evaluate the use of coregistered PET and CT (PET/CT) in patients with suspected thyroid cancer recurrence. METHODS: After total thyroidectomy followed by radioiodine ablation, 61 consecutive patients with elevated thyroglobulin levels or a clinical suspicion of recurrent disease underwent 18F-FDG PET/CT. Of these, 59 patients had negative findings on radioiodine (131I) whole-body scintigraphy (WBS). Fifty-three of the 61 patients had both negative 131I WBS findings and elevated thyroglobulin levels. PET/CT images were acquired 60 min after intravenous injection of 400-610 MBq of 18F-FDG using a combined PET/CT scanner. Any increased 18F-FDG uptake was compared with the coregistered CT image to differentiate physiologic from pathologic tracer uptake. 18F-FDG PET/CT findings were correlated with the findings of histology, postradioiodine WBS, ultrasound, or clinical follow-up serving as a reference. The diagnostic accuracy of 18F-FDG PET/CT was evaluated for the entire patient group and for those patients with serum thyroglobulin levels of less than 5, 5-10, and more than 10 ng/mL. RESULTS: Thirty patients had positive findings on 18F-FDG PET/CT; 26 were true-positive and 4 were false-positive. In 2 patients, increased 18F-FDG uptake identified a second primary malignancy. 18F-FDG PET/CT results were true-negative in 19 patients and false-negative in 12 patients. The overall sensitivity, specificity, and accuracy of 18F-FDG PET/CT were 68.4%, 82.4%, and 73.8%, respectively. The sensitivities of 18F-FDG PET/CT at serum thyroglobulin levels of less than 5, 5-10, and more than 10 ng/mL were 60%, 63%, and 72%, respectively. Clinical management changed for 27 (44%) of 61 patients, including surgery, radiation therapy, or chemotherapy. CONCLUSION: Coregistered 18F-FDG PET/CT can provide precise anatomic localization of recurrent or metastatic thyroid carcinoma, leading to improved diagnostic accuracy, and can guide therapeutic management. In addition, the findings of this study suggest that further assessment of 131I WBS-negative, thyroglobulin-positive patients by 18F-FDG PET/CT may aid in the clinical management of selected cases regardless of the thyroglobulin level. |
| | |
Authors:
|
Amer Shammas; Berna Degirmenci; James M Mountz; Barry M McCook; Barton Branstetter; Badreddine Bencherif; Badreddine B Bencherif; Judith M Joyce; Sally E Carty; Haruko A Kuffner; Norbert Avril |
Related Documents
:
|
12409108 - Special interest radiology improves the perceived preoperative stage of gastric cancer. 11443448 - Diagnostic laparoscopy and laparoscopic ultrasonography optimize the staging and resect... 19544378 - Revisiting the role of positron-emission tomography/computed tomography in determining ... 10741278 - Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging us... 15486208 - Venous compression at high-spatial-resolution three-dimensional mr angiography of perip... 16377488 - A case of pulmonary synovial sarcoma diagnosed with detection of chimera gene: imaging ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: 48 ISSN: 0161-5505 ISO Abbreviation: J. Nucl. Med. Publication Date: 2007 Feb |
Date Detail:
|
Created Date: 2007-02-01 Completed Date: 2007-04-06 Revised Date: 2007-04-09 |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 221-6 Citation Subset: IM |
Affiliation:
|
Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over False Negative Reactions False Positive Reactions Female Fluorodeoxyglucose F18 / diagnostic use Humans Image Processing, Computer-Assisted Iodine Radioisotopes / diagnostic use Male Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local Radiopharmaceuticals / diagnostic use Thyroglobulin / analysis Thyroid Gland / pathology, radiography, radionuclide imaging Thyroid Neoplasms / pathology, radiography*, radionuclide imaging* Whole Body Imaging |
| Chemical | |
Reg. No./Substance:
|
0/Iodine Radioisotopes; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18; 9010-34-8/Thyroglobulin |
| Comments/Corrections | |
Erratum In:
|
J Nucl Med. 2007 Mar;48(3):412 Note: Bencherif, Badreddine B [corrected to Bencherif, Badreddine] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Accuracy of PET/CT in characterization of solitary pulmonary lesions.
Next Document: Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correl...